About: A novel antiviral formulation inhibits a range of enveloped viruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A novel antiviral formulation inhibits a range of enveloped viruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A novel antiviral formulation inhibits a range of enveloped viruses
Creator	Bailey, Dalan Chaudhry, Yasmin Pingen, Marieke Baird, Alan Bryden, Steven Fletcher, Nicola Folan, Michael Gonçalves-Carneiro, Daniel Lefteri, Daniella Lowe, Claire Mckimmie, Clive Meredith, Luke Tidswell, Emma
topic	covid:e9a992d021be02f0c12d7c7e63076d862a300bee#this
source	BioRxiv
abstract	Some free fatty acids derived from milk and vegetable oils are known to have potent antiviral and antibacterial properties. However, therapeutic applications of short to medium chain fatty acids are limited by physical characteristics such as immiscibility in aqueous solutions. We evaluated a novel proprietary formulation based on an emulsion of short chain caprylic acid, ViroSAL, for its ability to inhibit a range of viral infections in vitro and in vivo. In vitro, ViroSAL inhibited the enveloped viruses Epstein-Barr, measles, herpes simplex, Zika and orf parapoxvirus, together with Ebola, Lassa, vesicular stomatitis and SARS-CoV-1 pseudoviruses, in a concentration- and time-dependent manner. Evaluation of the components of ViroSAL revealed that caprylic acid was the main antiviral component; however, the ViroSAL formulation significantly inhibited viral entry compared with caprylic acid alone. In vivo, ViroSAL significantly inhibited Zika and Semliki Forest Virus replication in mice following the inoculation of these viruses into mosquito bite sites. In agreement with studies investigating other free fatty acids, ViroSAL had no effect on norovirus, a non-enveloped virus, indicating that its mechanism of action may be via surfactant disruption of the viral envelope. We have identified a novel antiviral formulation that is of great interest for prevention and/or treatment of a broad range of enveloped viruses.
has issue date	2020-03-30(xsd:dateTime)
bibo:doi	10.1101/2020.03.29.009464
has license	biorxiv
sha1sum (hex)	e9a992d021be02f0c12d7c7e63076d862a300bee
schema:url	https://doi.org/10.1101/2020.03.29.009464
resource representing a document's title	A novel antiviral formulation inhibits a range of enveloped viruses
schema:publication	bioRxiv
resource representing a document's body	covid:e9a992d021be02f0c12d7c7e63076d862a300bee#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/e9a992d021be02f0c12d7c7e63076d862a300bee
is schema:about of	named entity 'Lassa' named entity 'tissue culture' named entity 'bite' named entity 'Biomedical' named entity 'HFF' named entity 'simplex' named entity 'based' named entity 'glycoprotein' named entity 'foreskin' named entity 'sites' named entity 'Modified' named entity 'virus' named entity 'infection' named entity 'ABILITY TO' named entity 'FLS' named entity 'VSV' named entity 'TO INHIBIT' named entity 'SARS CORONAVIRUS' named entity 'PFU' named entity 'FORESKIN' named entity 'ANTIBACTERIAL' named entity 'ITS' named entity 'RANGE' named entity 'TITLE' named entity 'ANTIVIRAL' named entity 'FORMULATION' named entity 'applications' named entity 'light' named entity 'measles' named entity 'Epstein-Barr' named entity 'Virus' named entity 'acid' named entity 'skin cells' named entity 'studies' named entity 'viral infections' named entity 'infectious dose' named entity 'vesicular stomatitis' named entity 'In vivo' named entity 'immiscibility' named entity 'aqueous solutions' named entity 'eGFP' named entity 'mice' named entity 'TCID50' named entity 'Semliki' named entity 'antiviral' named entity 'Zika' named entity 'viral entry' named entity 'human immunodeficiency virus' named entity 'Zika' named entity 'foetal bovine serum' named entity 'foetal' named entity 'tissue culture infectious dose' named entity 'Dulbecco' named entity 'caprylic acid' named entity 'pseudoviruses' named entity 'antiviral' named entity 'antibacterial' named entity 'SARS coronavirus' named entity 'plaque forming units' named entity 'human' named entity 'neonatal' named entity 'RNA' named entity 'orders of magnitude' named entity 'serum' named entity 'tissue culture infectious dose' named entity 'EGFP' named entity 'milk fat' named entity 'cDNA' named entity 'amphipathic' named entity 'antimicrobial activity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software